Orbit CEO, Neil Butt, will be speaking at the upcoming 5th Annual GPCR-Targeted Drug Discovery Summit in Boston later this month.
He will be giving a talk which describes how Orbit's functional peptide screening platform was used to find novel activators of the Mu and Delta Opioid Receptors.
Get in touch to learn more about how Orbit's platforms extend peptide discovery beyond finding simple binders and into identifying powerful functional modulators